On 5 October 2023, Kaneka Corporation filed a complaint against Cocrystal Technology (Jiaxing) Co., Ltd and Cocrystal Health Industry (Zhejiang) Co., Ltd (collectively "CoCrystal") in the US District Court for the Eastern District of New York.
The company alleges that its supplements containing reduced coenzyme Q10, also known as "ubiquinol," infringe claims 5 and 15 of Kaneka's US Patent No. 7,829,080 (the "'080 Patent" or "Patent").
On 2 September 2026, the New York District Court dismissed this litigation, holding that the Patent is invalid for lack of enablement.
This decision was issued despite the fact that Kaneka submitted tests showing significant utility during the Patent's application and that a District Court in Delaware had previously held the Patent valid.
Kaneka strongly disagrees with the New York District Court's legal decision and interpretation of the evidence supporting the Patent's validity and significant utility.
Kaneka will immediately appeal the decision to the Federal Circuit Court of Appeals.
The protection of Kaneka's intellectual property stands as a paramount cornerstone of its business. Kaneka's commitment to safeguarding these rights is unwavering.
It will not hesitate to take decisive legal action against anyone who fails to respect Kaneka's intellectual property, including its 080 Patent and other patents pertaining to reduced coenzyme Q10.
In the lawsuit against CoCrystal, Kaneka is fully prepared to, and will, vigorously enforce its patent rights to the fullest extent.
